世界のヒトマイクロバイオーム免疫治療市場(~2025):臨床試験インサイト

◆英語タイトル:Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025
◆商品コード:KUIK21FB010
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2020年8月
◆ページ数:300
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Multi UserUSD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のヒトマイクロバイオーム免疫治療市場について調査・分析を行い、マイクロバイオーム概要、人体におけるマイクロバイオームの役割、形態別マイクロバイオーム、マイクロバイオーム活性メカニズム、マイクロバイオータの技術的要件、マイクロバイオーム免疫の必要性、マイクロバイオーム免疫の治療への応用、感染症におけるヒトマイクロバイオータ、ヒトマイクロバイオータ・肝臓疾患、ヒトマイクロバイオータ・代謝障害、ヒトマイクロバイオータ・その他の疾患、免疫腫瘍学におけるマイクロバイオーム、がん種類別(胃がん、結腸直腸がん、食道がん、肝細胞癌がん、黒色腫)分析、産業アプローチ、市場分析、臨床パイプライン、主要企業による投資、買収・コラボレーション、将来見通し、競争状況などを掲載しています。
・マイクロバイオーム概要
・人体におけるマイクロバイオームの役割
・形態別マイクロバイオーム
・マイクロバイオーム活性メカニズム
・マイクロバイオータの技術的要件
・マイクロバイオーム免疫の必要性
・マイクロバイオーム免疫の治療への応用
・感染症におけるヒトマイクロバイオータ
・ヒトマイクロバイオータ・肝臓疾患
・ヒトマイクロバイオータ・代謝障害
・ヒトマイクロバイオータ・その他の疾患
・免疫腫瘍学におけるマイクロバイオーム
・世界のヒトマイクロバイオーム免疫治療市場:がん種類別(胃がん、結腸直腸がん、食道がん、肝細胞癌がん、黒色腫)
・産業アプローチ
・市場分析
・臨床パイプライン
・主要企業による投資・買収・コラボレーション
・将来見通し
・競争状況
【レポートの概要】

“Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025″ Report Highlights:

Global and Regional Market Insight
Global Human Microbiome Immunology Therapeutics Market: >US$ 1 Billion by 2025
US Dominates Global Market Landscape: >60% Market Share
Comprehensive Information on Ongoing clinical Trials and Potential Drug Candidates
Global Microbiome Modulator Drugs in Clinical Pipeline: >80 Drug in Trials
Therapeutic Applications of Microbiome Immunology by Indication
Clinical Trial Studies Related to Fecal Microbiota Transplant: > 250 Clinical Trials

The scale and scope of microbiome research activity has now become one of the fastest growing areas in biology. The relevance that it has shown for the welfare of the society and pharmaceutical industry has led to the development of a transdisciplinary environment that is however conducive to innovation with a mission to abolish the limitations in the pharmaceutical industry through excellence in microbiome research, awareness and outreach. Over the years now, gut microbiome is estimated to implicate success for the various immunotherapies.

Microbiome’s role in immunology practices is to transform the world-class treatment into the medicine of today and tomorrow. It is highly recognizable that the healthcare issues that mankind is facing today is now bigger than any one solution. The treatment of certain diseases requires multiple options for the treatment and ultimately prevention. Therefore, the amalgamation of two different treatment paradigms i.e. microbiome and immunology are apparently delivering some medical benefits that millions of patients were in need for long period of time. The ways in which microbiome is understood and manipulated to serve the immunological aspects has given great interest to all the researchers.

Essential and usual concept of immunology depicts targeting the immune system of the body to provoke an immune response with huge impact but then unsuccessful implication of immunology therapies driven treatments led to exploration of several other basic concepts that could play an important role in boosting the immune system when combined. Looking forward, the microbiome community in the gut represented beneficial patterns with respect to further research. The area of microbiome research and its combination with immunological aspect for the disease treatment has produced a real excitement in the area of medical research and specifically microbiome research.

All over the world, the amalgamation of the two has been well accepted and appreciated by the patients, physicians and the clinicians. Investigation of all the working sides of microbiome and how it plays an important role in boosting the manipulated immune cells have recently started in large numbers as the technology available in the medical field allows to capture it accurately. To facilitate the microbiome and immunology community in order to extract the best and trending opportunities that are stemmed into the microbiome research, the experts from both the relevant disciplines are analyzing it through clinical researches and surveys. Further, the area is getting supported by 86 different clinical trials getting conducted in different countries.

“Global Human Microbiome Immunology Therapeutics Market and Clinical Trial Insight 2025″ report summarizes the view of the wider opportunities that are associated microbiome community for the advancement of the scientific information regarding immunology. The science that is related with microbiome has high interdisciplinary and various opportunities that somehow have remained hidden in the medical world. It is believed that the opportunities and all the desirable tangible benefits microbiome is capable of delivering when combined with immunology is large and needs coordinated and constructive approach. The call to the two different sectors i.e. microbiology and immunology is estimated to unlock the potential and promising benefits of microbiome. The approach leading to the extraction of advantages if properly embedded in the microbiome and immunology research, the future benefits will be huge.

【レポートの目次】

Overview of Microbiome
1.1 Introduction to Microbiome
1.2 History and Evolution of Microbiome

Role of Microbiome in Human Body

Microbiome: Various Forms
3.1 Gut Microbiome
3.2 Lung Microbiome
3.3 Skin Microbiome
3.4 Microbiome in Other Parts of the Body

Mechanism of Microbiome Activity
4.1 Nature of Immune Response
4.1.1 Immunosuppressive Activity
4.1.2 Immunostimulatory Activity
4.2 Messengers Involves in Microbiome Mechanism
4.2.1 MAMPs/PAMPs
4.2.2 Microbial Metabolites As Messengers
4.2.3 Host Cytokines As Messengers
4.2.4 Immune Cells As Messengers

Technological Requirement for Microbiota
5.1 Technologies Used
5.1.1 iChip
5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
5.1.3 Gut-on-a-Chip System
5.1.4 Colonic Stem Cell Construction
5.2 Harnessing and Engineering the Microbiome
5.2.1 Additive Approaches
5.2.2 Subtractive Approaches

Need for Microbiome Immunology

Therapeutic Applications of Microbiome Immunology
7.1 Microbiome Therapy
7.2 Precision Medicine
7.3 Drug discovery
7.4 Biomarkers and Therapy Optimization

Human Microbiota in Infectious Diseases
8.1 Infection with Clostridium Difficile
8.2 Infection with Helicobacter Pylori
8.3 Bacterial Vaginosis
8.4 Infection with HIV

The Human Microbiota and Liver Diseases
9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)
9.2 Alcoholic Liver Diseases (ALD)
9.3 Liver Fibrosis and Cirrhosis

The Human Microbiota and Metabolic Disorders
10.1 Obesity
10.2 Type 2 Diabetes

The Human Microbiota and Other Diseases
11.1 Microbiota and Allergic Diseases
11.2 Microbiota and Psychiatric Diseases

Microbiome in Immuno Oncology
12.1 Role of Microbiome in Immuno Oncology
12.2 Microbiome Mechanism in Oncogenesis and Tumor Suppression

Microbiome Application by Cancer Types
13.1 Gastric Cancer
13.2 Colorectal Cancer
13.3 Esophageal Cancer
13.4 Hepatocellular Carcinoma
13.5 Melanoma
13.6 Solid Tumors

Industrial Approaches of Microbiome Therapy in Oncology
14.1 Bacterial Approaches
14.1.1 Fecal Microbiota Transplantation (FMT)
14.1.2 Synthetic Bacteria
14.1.3 Microbial Culture
14.2 Microbiome as Vaccine
14.3 Microbiome as Small Molecules
14.4 Microbiome Therapy using Phage Virus

Global Human Microbiome Market Analysis
15.1 Overview
15.2 Human Microbiome Market Segmentation
15.2.1 Regional Segmentation
15.2.2 Disease Based Segmentation
15.2.3 Segmentation by Application

Clinical Pipeline of Microbiome Based Therapy
16.1 Microbiome Modulators in Clinical Trial
16.2 Cancer Related Clinical Trials
16.2.1 Preclinical and Discovery Phase
16.2.2 Active Clinical Trials
16.3 Clinical Trial Related To FMT
16.3.1 Clinical Trial for Recurrent C. difficile
16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)
16.3.3 Other FMT Related Clinical Trials

Global Microbiome Modulators Clinical Pipeline By Company, Indication and Phase
17.1 Research
17.2 Preclinical
17.3 Clinical
17.4 Phase-I
17.5 Phase-I/II
17.6 Phase-II
17.7 Phase-II/III
17.8 Phase-III

Marketed Microbiome Modulators Clinical Insight
18.1 Sodium Oligomannurarate – Shanghai Green Valley Pharmaceutical
18.2 Miya-BM

Global Microbiome Immunology Therapeutics Market Growth Drivers

Microbiome Technology – Investments, Acquisitions and Collaborations by Leading Microbiome Companies

Blockades in the Microbiome Immunology Market
21.1 Stable Engraftment
21.2 Development of Clinically Relevant Sensors
21.3 Robustness and Evolutionary Stability of Genetic Circuits
21.4 Regulation, Safety and Biocontainment

Global Microbiome Immunology Market Future Panorama

Competitive Landscape
23.1 4D Pharma
23.2 AbbVie
23.3 AstraZeneca plc
23.4 Biocodex
23.5 Bristol Mayer Squibb
23.6 Corebiome/Diversigen
23.7 Elogi Bioscience
23.8 Enterome
23.9 Ferring Pharmaceuticals
23.10 Finch Therapeutics
23.11 Maat Pharma
23.12 Merck
23.13 Microbiome Therapeutics
23.14 Novartis
23.15 OpenBiome
23.16 Pfizer
23.17 Rebiotix
23.18 Second Genome
23.19 Seres Therapeutics
23.20 Symberix
23.21 Takeda Pharmaceuticals
23.22 Vedanta Bioscience



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のヒトマイクロバイオーム免疫治療市場(~2025):臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆